Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer

BACKGROUND: Concurrent epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI) with radiotherapy in patients with EGFR‐mutant unresectable stage III non‐small cell lung cancer (NSCLC) might improve survival. However, both treatments carry a potential risk of pneumonitis. METHODS: Betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Kunpeng, Liang, Jun, Zhang, Tao, Zhou, Zongmei, Chen, Dongfu, Feng, Qinfu, Xiao, Zefen, Hui, Zhouguang, Lu, Jima, Wang, Xin, Deng, Lei, Liu, Wenyang, Wang, Jianyang, Zhai, Yirui, Wang, Jie, Bi, Nan, Wang, Luhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952784/
https://www.ncbi.nlm.nih.gov/pubmed/33501781
http://dx.doi.org/10.1111/1759-7714.13816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952784/
https://www.ncbi.nlm.nih.gov/pubmed/33501781
http://dx.doi.org/10.1111/1759-7714.13816

Ejemplares similares